Medpace Holdings, Inc. logo
Medpace Holdings, Inc. (MEDP)
Compare

Medpace Holdings, Inc. (MEDP) Average EV/EBITDA Ratio

EV/EBITDA Ratio

The current ev/ebitda ratio for Medpace Holdings, Inc. (MEDP) is 21.18x as of Thursday, June 18, 2026, shown against its trailing averages.

Average EV/EBITDA Ratio Chart

MEDP EV/EBITDA Ratio Averages

EV/EBITDA RATIO CURRENT

21.18x

EV/EBITDA RATIO TTM

26.03x

EV/EBITDA RATIO 3Y

25.80x

EV/EBITDA RATIO 5Y

25.61x

EV/EBITDA RATIO 10Y

22.53x

EV/EBITDA RATIO 15Y

22.53x

EV/EBITDA RATIO 20Y

22.53x

About Medpace Holdings, Inc.

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Cincinnati, OH
5,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
August James Troendle